• Age ≥18 years.

• Histologically or cytologically confirmed advanced solid tumor.

• Failure of at least one line of standard therapy, or no standard treatment available, or intolerant to standard treatment at the current stage.

• At least one measurable lesion according to RECIST 1.1 criteria.

• ECOG performance status of 0-1.

• Expected survival ≥3 months.

• Sufficient organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factor treatment within 14 days):

‣ Absolute neutrophil count (ANC) ≥1.5×10⁹/L;

⁃ Platelets (PLT) ≥90×10⁹/L;

⁃ Hemoglobin (Hb) ≥90 g/L;

⁃ Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma);

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma);

⁃ Creatinine clearance (Ccr) \>50 mL/min (calculated by Cockcroft-Gault formula);

⁃ Activated partial thromboplastin time (APTT) ≤1.5×ULN; INR ≤1.5×ULN.

• Fertile participants (male and female) must agree to use reliable contraception (hormonal, barrier, or abstinence) with their partners during the trial and for at least 180 days after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.

• Understand and voluntarily sign the informed consent form (ICF).